| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5952375 | ROCHE | Compounds and methods for synthesis and therapy |
Feb, 2015
(9 years ago) | |
|
US5952375 (Pediatric) | ROCHE | Compounds and methods for synthesis and therapy |
Aug, 2015
(8 years ago) | |
| US5866601 | ROCHE | Carbocyclic compounds |
Feb, 2016
(8 years ago) | |
|
US5866601 (Pediatric) | ROCHE | Carbocyclic compounds |
Aug, 2016
(7 years ago) | |
| US5763483 | ROCHE | Carbocyclic compounds |
Dec, 2016
(7 years ago) | |
|
US5763483 (Pediatric) | ROCHE | Carbocyclic compounds |
Jun, 2017
(6 years ago) | |
Tamiflu is owned by Roche.
Tamiflu contains Oseltamivir Phosphate.
Tamiflu has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Tamiflu are:
- US5952375
- US5952375*PED
- US5866601
- US5866601*PED
- US5763483
- US5763483*PED
Tamiflu was authorised for market use on 02 July, 2007.
Tamiflu is available in capsule;oral, for suspension;oral dosage forms.
Tamiflu can be used as treatment and prophylaxis of influenza.
The generics of Tamiflu are possible to be released after 02 August, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-251) | Aug 02, 2022 |
| M(M-90) | Feb 22, 2013 |
| New Patient Population(NPP) | Dec 21, 2015 |
Drugs and Companies using OSELTAMIVIR PHOSPHATE ingredient
Market Authorisation Date: 02 July, 2007
Treatment: Treatment and prophylaxis of influenza
Dosage: CAPSULE;ORAL; FOR SUSPENSION;ORAL
TAMIFLU family patents
